Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years)

Next Previous
X
Search
Trial Profile

Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; AS04A; Hepatitis A vaccine
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 22 Jun 2012 Actual patient number changed from 551 to 529 as reported by ClinicalTrials.gov record (Extension trial: NCT00877877).
    • 02 Jun 2012 Planned patient number for the follow up trial (EudraCT2008-000369-44) is now 600.
    • 19 Apr 2012 Actual patient number changed from 529 to 551 as reported by ClinicalTrials.gov record (Extension trial: NCT00877877).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top